Contents

01 January 2014
Vol 6, Issue 217

About The Cover

Cover image expansion

ONLINE COVER Immunotherapy Hits the Mark. Tumor immunotherapy is a promising new strategy for cancer treatment but is somewhat limited by the immunosuppressive nature of the tumor microenvironment. Type I interferons (IFNs) have been shown to promote tumor immunity, but systemic toxicity has limited their use. Now, Escobar et al. attempt to overcome this immunosuppression by introducing IFN-α into tumor-infiltrating macrophages. These cells inhibit tumor progression and experimental metastasis in a model of breast cancer, effectively reprogramming the tumor microenvironment. [CREDIT: PEEPO/ISTOCKPHOTO]